Inmunoanálisis enzimático (ELISA) en la evolución terapéutica de la cromoblastomicosis por Cladophialophora carrionii en el área endémica del Estado Falcón, Venezuela

Oberto-Perdigón, Lairet; Romero, Hilda; Pérez-Blanco, M.; Apitz‐Castro, Rafael

doi:10.1016/s1130-1406(05)70005-x

Cited by 18 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The somatic antigen produced with C. carrionii was analyzed in an ELISA assay during the therapeutic evolution in patients with CBM caused by C. carrionii. In this study, 100% of the serum of patients with CBM was shown to react to this antigen before treatment, but the serum of healthy people did not react, suggesting that it is an important tool for diagnosing active disease [162]. Furthermore, it was verified by immunoblotting that an antigenic fraction of 54 kDa purified from F. pedrosoi reacted positively in 96.7% when incubated with serum from patients with CBM caused by F. pedrosoi, and, importantly, this antigen did not cross-react with serum from patients with sporotrichosis, leishmaniasis, or healthy people [163].…”

Section: Immunological Diagnosismentioning

confidence: 59%

Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis

Passero

Cavallone

Belda

2021

Journal of Immunology Research

View full text Add to dashboard Cite

Chromoblastomycosis (CBM) is a neglected human disease, caused by different species of pigmented dematiaceous fungi that cause subcutaneous infections. This disease has been considered an occupational disease, occurring among people working in the field of agriculture, particularly in low-income countries. In 1914, the first case of CBM was described in Brazil, and although efforts have been made, few scientific and technological advances have been made in this area. In the field of fungi and host cell relationship, a very reduced number of antigens were characterized, but available data suggest that ectoantigens bind to the cell membrane of host cells and modulate the phagocytic, immunological, and microbicidal responses of immune cells. Furthermore, antigens cleave extracellular proteins in tissues, allowing fungi to spread. On the contrary, if phagocytic cells are able to present antigens in MHC molecules to T lymphocytes in the presence of costimulation and IL-12, a Th1 immune response will develop and a relative control of the disease will be observed. Despite knowledge of the resistance and susceptibility in CBM, up to now, no effective vaccines have been developed. In the field of chemotherapy, most patients are treated with conventional antifungal drugs, such as itraconazole and terbinafine, but these drugs exhibit limitations, considering that not all patients heal cutaneous lesions. Few advances in treatment have been made so far, but one of the most promising ones is based on the use of immunomodulators, such as imiquimod. Data about a standard treatment are missing in the medical literature; part of it is caused by the existence of a diversity of etiologic agents and clinical forms. The present review summarizes the advances made in the field of CBM related to the diversity of pathogenic species, fungi and host cell relationship, antigens, innate and acquired immunity, clinical forms of CBM, chemotherapy, and diagnosis.

show abstract

Section: Immunological Diagnosismentioning

confidence: 59%

Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis

Passero

Cavallone

Belda

2021

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…used ELISA in 114 sera to assess the humoral response before, during, and after treatment employing a somatic antigen (AgSPP) of C. carrionii . 93 The authors concluded that the method is valuable for diagnosis and assessment of therapeutic efficacy. However, PCR and ELISA are still not available in many endemic areas.…”

Section: Laboratory Diagnosismentioning

confidence: 99%

Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update

Brito

Bittencourt

2018

An. Bras. Dermatol.

View full text Add to dashboard Cite

Chromoblastomycosis is a chronic, granulomatous, suppurative mycosis of the skin and subcutaneous tissue caused by traumatic inoculation of dematiaceous fungi of the family Herpotrichiellaceae. The species Fonsecaea pedrosoi and Cladophialophora carrionii are prevalent in regions where the disease is endemic. Chromoblastomycosis lesions are polymorphous: verrucous, nodular, tumoral, plaque-like, and atrophic. It is an occupational disease that predominates in tropical and subtropical regions, but there have been several reports of cases in temperate regions. The disease mainly affects current or former farm workers, mostly males, and often leaving disabling sequelae. This mycosis is still a therapeutic challenge due to frequent recurrence of lesions. Patients with extensive lesions require a combination of pharmacological and physical therapies. The article provides an update of epidemiological, clinical, diagnostic, and therapeutic features.

show abstract

Association of IgG immunoglobulin and subclasses level with the severity of chromoblastomycosis due to Fonsecaea pedrosoi and therapeutic response to itraconazole

Azevedo

Bruña–Romero

Marques

et al. 2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Chromoblastomycosis (CBM) is a chronic, suppurative, granulomatous mycosis of the skin and subcutaneous tissues. The aim of this study was to evaluate the association between IgG antibody levels and the severity of CBM and therapeutic response of patients to itraconazole. A longitudinal study was conducted in patients with CBM due to Fonsecaea pedrosoi and in healthy subjects with chromomycin skin test (CST)+. The dosage of anti-F. pedrosoi IgG antibody performed in 47 healthy individuals with CST+ showed positivity in 97.5 %, with an average titer of 2,109 [standard deviation (SD) + 3,676)] and a mean optical density (OD) of 1.174 (SD + 0.456), showing positive correlation with the induration area of the CST (mm(2)). The level of antibodies in 55 patients with CBM expressed in OD and titration showed that, before treatment, patients with severe disease had higher levels of IgG, IgG1, IgG2, and IgG3 when compared with moderate or mild disease (p < 0.05). According to the time of treatment, the mean antibody titers of IgG, IgG1, and IgG2 were reduced after treatment (p < 0.05). In the assessment of therapeutic response, there was reduction of IgG3 and IgG titers in patients with rapid response (p < 0.05) and IgG2 on rapid and intermediate response (p < 0.05). There was clear evidence of what are the risk factors for exposure to F. pedrosoi in the daily lives of these subjects, with prospects of preventive measures for the target population. The immunological analysis shows that the antibody anti-F. pedrosoi did not exhibit a protective role against infection caused by this agent.

show abstract

Inmunoanálisis enzimático (ELISA) en la evolución terapéutica de la cromoblastomicosis por Cladophialophora carrionii en el área endémica del Estado Falcón, Venezuela

Cited by 18 publications

References 10 publications

Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis

Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis

Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update

Association of IgG immunoglobulin and subclasses level with the severity of chromoblastomycosis due to Fonsecaea pedrosoi and therapeutic response to itraconazole

Contact Info

Product

Resources

About